Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyl-CpG-binding domain protein 3-like 1 (MBD3L1) is a protein-coding gene product homologous to MBD2 and MBD3, but notably lacks the canonical methyl-CpG-binding domain that enables binding to methylated DNA. Instead, MBD3L1 interacts with members of the NuRD (nucleosome remodeling and deacetylase) complex, specifically MBD2 and MBD3, acting as a transcriptional repressor within certain chromatin contexts. It is expressed predominantly in round spermatids of the testis, suggesting a specialized role in postmeiotic germ cell development. Though it can modulate key gene silencing complexes, knockout studies in mice suggest functional redundancy or a nonessential role under normal conditions. In cell models of facioscapulohumeral muscular dystrophy, DUX4-driven MBD3L1 expression may contribute to loss of required gene repression[1][2][4][6]. There is no evidence supporting MBD3L1 as a clinical therapeutic target or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyl-CpG-binding domain protein 3-like 1 (MBD3L1).